Nicolas Fakhry

Nicolas Fakhry

Auto-generated profile, based on publicly available information

Nicolas Fakhry

Department of Otolaryngology–Head and Neck Surgery Aix‐Marseille University Marseille AP‐HM France

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2020 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
RGRenaud Garrel
Renaud Garrel
GPGilles Poissonnet
Gilles Poissonnet
APAntoine Moyà Plana
Antoine Moyà Plana
NFNicolas Fakhry
Nicolas Fakhry
GDGilles Dolivet
Gilles Dolivet
MBMarie De Boutray
Marie De Boutray
PURPOSE: Sentinel node (SN) biopsy is accurate in operable oral and oropharyngeal cT1-T2N0 cancer (OC), but, to our knowledge, the oncologic equivalence of SN biopsy and neck lymph node dissection (ND; standard treatment) has never been evaluated.METHODS: In this phase III multicenter trial, 307 patients with OC were randomly assigned to (1) the ND arm or (2) the SN arm (experimental arm: biopsy alone if negative, or followed by ND if positive, during primary tumor surgery). The primary outcome was neck node recurrence-free survival (RFS) at 2 years. Secondary outcomes were 5-year neck node RFS, 2- and 5-year disease-specific survival (DSS), and overall survival (OS). Other outcomes were hospital stay length, neck and shoulder morbidity, and number of physiotherapy prescriptions during the 2 years after surgery.RESULTS: Data on 279 patients (139 ND and 140 SN) could be analyzed. Neck node RFS was 89.6% (95% CI, 0.83% to 0.94%) at 2 years in the ND arm and 90.7% (95% CI, 0.84% to 0.95%) in the SN arm, confirming the equivalence with P < .01. The 5-year RFS and the 2- and 5-year DSS and OS were not significantly different between arms. The median hospital stay length was 8 days in the ND arm and 7 days in the SN arm ( P < .01). The functional outcomes were significantly worse in the ND arm until 6 months after surgery.CONCLUSION: This study demonstrated the oncologic equivalence of the SN and ND approaches, with lower morbidity in the SN arm during the first 6 months after surgery, thus establishing SN as the standard of care in OC.

1 May 2020 in European Journal of Cancer
Verified
Journal Article
Closed access
SASarah Atallah
Sarah Atallah
OCOdile Casiraghi
Odile Casiraghi
NFNicolas Fakhry
Nicolas Fakhry
MWMichel Wassef
Michel Wassef
EUEmmanuelle Uro-Coste
Emmanuelle Uro-Coste
BBBertrand BAUJAT
Bertrand BAUJAT

1 September 2020 in Oral Oncology
Verified
Journal Article
Closed access
CECarlos M Chiesa Estomba
Carlos M Chiesa Estomba
JLJérome R. Lechien
Jérome R. Lechien
CCChristian Calvo-Henríquez
Christian Calvo-Henríquez
NFNicolas Fakhry
Nicolas Fakhry
PKPetros D. Karkos
Petros D. Karkos
TATareck Ayad
Tareck Ayad

1 March 2021 in European Journal of Cancer
Verified
Journal Article
Open access
CHCaroline Hoffmann
Caroline Hoffmann
VCValentin CALUGARU
Valentin CALUGARU
EBEdith Borcoman
Edith Borcoman
Victor MorenoVictor Moreno
Victor Moreno
ECEmiliano Calvo
Emiliano Calvo
Christophe Le TourneauChristophe Le Tourneau
Christophe Le Tourneau
This phase I study assessed the safety of first-in-class radioenhancer nanoparticles, NBTXR3, in elderly or frail patients with locally advanced head and neck squamous cell carcinoma (HNSCC), ineligible for chemoradiation. Patients with stage III or IVA (American Joint Committee on Cancer (AJCC) guidelines, 7th edition, 2010) HNSCC of the oral cavity or oropharynx, aged ≥70 or ≥65 years and ineligible to receive cisplatin, amenable to radiotherapy (RT) with curative intent, received NBTXR3 as a single intratumoural (IT) injection followed by activation by intensity-modulated radiation therapy (IMRT; 70 Gy). The NBTXR3 dose corresponded to a percentage of the baseline tumour volume, measured by magnetic resonance imaging. The primary objectives were to determine the recommended phase II dose (RP2D), dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD). Safety and tolerability were assessed using National Cancer Institute CTCAE version 4.0. Antitumour activity was assessed by Response Evaluation Criteria in Solid Tumours 1.1. Nineteen patients were enrolled: 3 at the dose level of 5%, 3 at the dose level of 10%, 5 at the dose level of 15% and 8 at the dose level of 22% of the tumour volume. The MTD was not reached, and no DLTs or serious adverse event (SAEs) related to NBTXR3 were observed. Four adverse events related to NBTXR3 and/or the IT injection were reported (grade I-II). NBTXR3 remained in the injected tumour throughout RT, with no leakage in the surrounding healthy tissues. Specific RT-related toxicity was as expected with IMRT. The RP2D was determined as 22% baseline tumour volume. Preliminary signs of antitumour activity were observed. Intratumoural injection of NBTXR3 followed by IMRT is feasible and demonstrated a good safety profile, supporting further evaluation at the RP2D in this patient population. ClinicalTrials.govNCT01946867.

1 June 2012 in European Annals of Otorhinolaryngology, Head and Neck Diseases
Verified
Journal Article
Closed access
NFN. Fakhry
N. Fakhry
FAF. Antonini
F. Antonini
JMJ. Michel
J. Michel
MPM. Penicaud
M. Penicaud
JMJulien Mancini
Julien Mancini
AGA. Giovanni
A. Giovanni

1 May 2020 in European Annals of Otorhinolaryngology, Head and Neck Diseases
Verified
Journal Article
Closed access
NFN. Fakhry
N. Fakhry
PSP. Schultz
P. Schultz
SMS. Morinière
S. Morinière
IBI. Breuskin
I. Breuskin
ABA. Bozec
A. Bozec
BBB. Barry
B. Barry